PT-141 for sexual dysfunction: what TikTok gets wrong

What did @ashleysmells...good actually say?

The creator says she just received PT-141 and frames it as one of the peptides that "definitely work" alongside what sounds like a coded reference to GLP-1 medications. She also floats the idea that some peptides are "actually approved" by the FDA for "certain issues," which is doing a lot of work in not very many words.

To be fair: she's being deliberately vague, spelling out "F-D-A" and describing PT-141's indication as "a certain issue." That kind of coded language is a TikTok adaptation to avoid takedowns, not necessarily bad faith. But vague framing can mislead viewers who don't already know the specifics. If you're going to stake a claim on FDA approval, you owe your audience the full picture.

Does the science back this up?

On the core claim, yes. PT-141, generically known as bremelanotide, is legitimately FDA-approved. That's not a grey area. The agency cleared it in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. That's a real indication backed by clinical trial data.

The mechanism is worth understanding. Bremelanotide is a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors like sildenafil, it works on desire at the brain level rather than blood flow mechanics. The pivotal trials (Kingsberg et al., 2019, Obstetrics and Gynecology) showed statistically significant improvements in sexual desire scores and reductions in distress compared to placebo, though effect sizes were modest and nausea was a notable side effect in a substantial portion of participants. A 2019 review in the Journal of Sexual Medicine by Simon et al. confirmed the approval profile. This is not vaporware. The pharmacology is real.

What did they get wrong (or right)?

She got the FDA approval claim right, which is more than most peptide TikTok accounts manage. Credit where it's due. But the framing that some peptides "definitely work" while others are speculative, and lumping PT-141 in with GLP-1 drugs as similarly validated, creates a false equivalency problem.

GLP-1 receptor agonists like semaglutide have an enormous body of evidence behind them, including large cardiovascular outcomes trials. Comparing their evidence base to PT-141, or to the broader peptide category she gestures at, glosses over major differences in research depth and regulatory history. The other peptides she hashtags in her content, BPC-157, TB-500, CJC-1295, MK-677, have nowhere near the human clinical trial data that would support that same "definitely works" confidence level.

She also doesn't mention that compounded versions of bremelanotide, which is what most telehealth and online sources actually sell, are not the same as FDA-approved Vyleesi. Compounded drugs aren't FDA-approved products. That's a meaningful distinction she skips entirely.

What should you actually know?

PT-141 as bremelanotide has a legitimate FDA approval, but that approval is specific: HSDD in premenopausal women. It is not approved for men, though off-label use in men is being studied and discussed in clinical settings. It is not approved for general sexual enhancement, performance optimization, or the kinds of "biohacking" use cases that dominate peptide TikTok.

Compounded PT-141, which most people are actually getting from telehealth platforms or peptide suppliers, is not FDA-approved. Full stop. The FDA has flagged compounded bremelanotide specifically on its list of drugs that raise safety concerns when compounded, which matters when evaluating sourcing claims.

If you are interested in bremelanotide for an on-label indication, that is a conversation for a licensed provider who can review your full health history, not a TikTok video. Known side effects include nausea, flushing, and transient blood pressure increases. Those are not trivial for everyone.

The bottom line

This video is less wrong than the average peptide TikTok, which isn't saying much but is worth noting. The FDA approval point holds up. The broader implication that the peptide category is validated the way pharmaceuticals are does not. Viewers walking away thinking all these compounds have the same evidence base as approved drugs are being misled, even if unintentionally.

• PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women
• Compounded versions are not FDA-approved products and carry different regulatory risk
• The clinical trial data behind bremelanotide is real but shows modest effect sizes and notable side effects
• Off-label use, including in men, lacks the same evidence base as the approved indication